{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Siddiqi T"],"funding":["NCI NIH HHS"],"pagination":["309-317"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6982547"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["61(2)"],"pubmed_abstract":["Alisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with relapsed/refractory lymphoid malignancies (<i>N</i> = 34; NCT01567709). Patients received alisertib plus vorinostat in 21-day treatment cycles with escalating doses of alisertib following a continuous or an intermittent schedule. All dose-limiting toxicities (DLTs) were hematologic and there were no study-related deaths. The recommended phase 2 dose (RP2D) of the combination was 20 mg bid of alisertib and 200 mg bid of vorinostat on the intermittent schedule. A 13-patient expansion cohort was treated for a total of 18 patients at the RP2D. There were no DLTs at the RP2D, and toxicities were mainly hematologic. Two patients with DLBCL achieved a durable complete response, and two patients with HL achieved partial response. Alisertib plus vorinostat showed encouraging clinical activity with a manageable safety profile in heavily pretreated patients with advanced disease."],"journal":["Leukemia & lymphoma"],"pubmed_title":["Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies."],"pmcid":["PMC6982547"],"funding_grant_id":["P30 CA047904","UM1 CA186717","UM1 CA186690","P30 CA033572","R50 CA211241"],"pubmed_authors":["Ruel C","Puverel S","Siddiqi T","Frankel P","Kiesel BF","Kelly KR","Piekarz R","Beumer JH","Ailawadhi S","Forman SJ","Newman EM","Christner S","Popplewell L","Song JY","Kaesberg P","Chen R"],"additional_accession":[]},"is_claimable":false,"name":"Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.","description":"Alisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with relapsed/refractory lymphoid malignancies (<i>N</i> = 34; NCT01567709). Patients received alisertib plus vorinostat in 21-day treatment cycles with escalating doses of alisertib following a continuous or an intermittent schedule. All dose-limiting toxicities (DLTs) were hematologic and there were no study-related deaths. The recommended phase 2 dose (RP2D) of the combination was 20 mg bid of alisertib and 200 mg bid of vorinostat on the intermittent schedule. A 13-patient expansion cohort was treated for a total of 18 patients at the RP2D. There were no DLTs at the RP2D, and toxicities were mainly hematologic. Two patients with DLBCL achieved a durable complete response, and two patients with HL achieved partial response. Alisertib plus vorinostat showed encouraging clinical activity with a manageable safety profile in heavily pretreated patients with advanced disease.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Feb","modification":"2024-02-15T20:01:17.579Z","creation":"2021-02-21T04:29:56Z"},"accession":"S-EPMC6982547","cross_references":{"pubmed":["31617432"],"doi":["10.1080/10428194.2019.1672052"]}}